Drug Transporter (DT) Information

General Information of DT
DT ID DTD0028
Gene Name SLC47A2
Protein Name Multidrug and toxin extrusion protein 2
Gene ID
146802
UniProt ID
Q86VL8
TCDB ID
2.A.66.1.20
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; MATE2-B; MATE2-K; MATE2K; SLC47A2; Solute carrier family 47 member 2; hMATE-2
DT Family Multidrug/Oligosaccharidyl-Lipid/Polysaccharide (MOP) Flippase Superfamily
Multi Antimicrobial Extrusion (MATE) Family
Tissue Specificity Isoform 3 is predominantly expressed inkidney. Isoform 6 is expressed in brain.
Function This transporter is reesponsible for the secretion of cationic drugs across the brush border membranes, such as tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, and ganciclovir.
Disease(s) Cytomegalovirus infections [ICD-11: 1D82]
Ovarian cancer [ICD-11: 2C73]
Type 2 diabetes [ICD-11: 5A11]
Ventricular arrhythmias [ICD-11: BC71]
Herpes simplex virus infection [ICD-11: 1F00]
Maintenance of normal sinus rhythm [ICD-11: BC81.3]
Endogenous Substrate(s) H+
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            9 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Abemaciclib
 Approved Drug Info Breast cancer 2C60-2C6Z [1]
Acyclovir
 Approved Drug Info Shingles 1.00E+91 [2]
Cimetidine
 Approved Drug Info Acid reflux disorder DA22 [2]
Dofetilide
 Approved Drug Info Maintenance of normal sinus rhythm BC81.3 [3]
Estrone sulfate
 Approved Drug Info Menopausal symptoms MF32 [2]
Ganciclovir
 Approved Drug Info Cytomegalovirus infections 1D82 [2]
Metformin
 Approved Drug Info Type 2 diabetes 5A11 [2]
Procainamide
 Approved Drug Info Ventricular arrhythmias BC71 [2]
Topotecan
 Approved Drug Info Ovarian cancer 2C73 [2]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Tetraethylammonium
 Phase 2 Drug Info Hyperlipidaemia 5C8Z [2]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
N-methylpyridinium
 Preclinical Drug Info Colon cancer 2B90.Z [2]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            4 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Creatinine
588
EM Info Identified using HEK293 cells-MATE2 [4]
Guanidine
3520
EM Info Identified using HEK293 cells-MATE2 [4]
Testosterone
6013
EM Info Unclear experiment used for identifying this EM [5]
Thiamine
1130
EM Info Identified using HEK293 cells-MATE2 [4]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:          10 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Acyclovir Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 4320 microM [2]
Cimetidine Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 120 microM [2]
Cimetidine Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 370 microM [4]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 850 microM [2]
Ganciclovir Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 4280 microM [2]
Metformin Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 1050 microM [4]
Metformin Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 1980 microM [2]
Procainamide Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 1580 microM [2]
Procainamide Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 4100 microM [4]
Topotecan Approved Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 60 microM [2]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Tetraethylammonium Phase 2 Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 760 microM [2]
Tetraethylammonium Phase 2 Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 830 microM [4]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
N-methylpyridinium Preclinical Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 93.5 microM [4]
N-methylpyridinium Preclinical Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 110 microM [2]
References
1 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
2 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
3 FDA Drug Development and Drug Interactions
4 Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006 Aug;17(8):2127-35.
5 Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007 Jul;24(7):1227-51.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.